The purpose of the compassionate prescribing framework referred to in Article L. 5121-12-1 is to ensure the safety of prescribing a medicinal product which does not comply with its marketing authorisation, in order to meet the special needs of the patients concerned. It may be established, in the absence of an authorised medicinal product with the same active substance, the same pharmaceutical form and the same strength, when the conditions set out in I and III of Article L. 5121-12-1 are met.
The Director General of the Agence nationale de sécurité du médicament et des produits de santé may initiate the establishment of a compassionate prescribing framework, or initiate this procedure at the request of the Minister for Health or the Minister for Social Security.